Tag: MD

Poster-Case Reports / Case Series

Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Background: Bilateral involvement and severe visual impairment can occur in the acute phase of pediatric myelin oligodendrocyte...

Read More

Poster-Case Reports / Case Series

Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: Tinea corporis is a fungal infection of the skin excluding the face, hands, feet, scalp, nail, or groin. It mostly affects the...

Read More

Poster-Case Reports / Case Series

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

Background: The association of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) has been rarely reported. Objectives: To report a...

Read More

Poster-Case Reports / Case Series

Immunotherapy-Responsive Post COVID-19 Central Nervous System Inflammatory Syndrome, a Case Report

Background: COVID 19 virus can infect the central and peripheral nervous system with or without other systemic manifestations of infection....

Read More

Poster-Case Reports / Case Series

Case Report: Lama-2 Related Muscular Dystrophy Mimicking Multiple Sclerosis

Background: There is increased prevalence of genetic testing within the field of neurology and provider awareness of genetic conditions...

Read More

Poster-Disease-modifying Therapy

Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study

Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...

Read More

Poster-Case Reports / Case Series

Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate

Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to reduce...

Read More

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More

Platform-Rehabilitation

Spasticity Experience in Adults with Multiple Sclerosis: An Integrated Conceptual Model

Background: Spasticity is a common symptom of multiple sclerosis (MS), often leading to functional limitations and disability. Objectives:...

Read More

Platform-Disease Management

Characterizing Socioeconomic, Lifestyle, and Comorbidity Mediators of Racial Disparities in Ambulatory Impairments in Multiple Sclerosis.

Background: Multiple sclerosis (MS) is more prevalent in White Americans (WAs), yet incidence is now highest in Black Americans (BAs), who...

Read More